Top Markets
#1 MowCat MowCat +48.86%
#2 Velvet Velvet +22.01%
#3 Derive Derive +20.28%
#4 Quack AI Quack AI +19.40%
#5 SkyAI SkyAI +14.51%
#6 Geodnet Geodnet +14.11%
#7 Bermuda Shorts Bermuda Shorts +14.08%
#8 aPriori aPriori +13.09%
#9 Audiera Audiera +12.67%
#10 Cross Cross +11.92%
Coin of the day
MowCat MowCat
Instellingen
Taal
DUTCH
Valuta
USD
Thema
MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

MyMD Pharmaceuticals, Inc.

MYMD
Rang in aandelen #35400
MyMD Pharmaceuticals, Inc. is a pharmaceutical firm currently in the clinical... MyMD Pharmaceuticals, Inc. is a pharmaceutical firm currently in the clinical development stage, focused on devising diverse therapeutic strategies that target the underlying origins of various illnesses. One of its key initiatives is the development of MYMD-1, a drug platform centered on a small molecule presently undergoing clinical trials. This molecule works by regulating the immune system to suppress TNF-alpha, a major contributor to chronic inflammation, along with other pro-inflammatory cell-signaling proteins. MYMD-1 is being explored for its potential to delay aging, extend lifespan, manage autoimmune conditions, and treat depression linked to COVID-19. Furthermore, the company is advancing Supera-CBD, a synthetic version of cannabidiol, which aims to address chronic pain, addiction, and epilepsy. MyMD Pharmaceuticals was established in 2014 and its corporate headquarters are situated in Baltimore, Maryland.
Aandeelprijs
$1.85
Laatst gesynchroniseerd: 2024-08-19
Marktkapitalisatie
$3.96M
Verandering (1 dag)
2.78%
Verandering (1 jaar)
0.00%
Land
US
Handel MyMD Pharmaceuticals, Inc. (MYMD)

Categorie

Healthcare
Winst voor MyMD Pharmaceuticals, Inc. (MYMD)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van MyMD Pharmaceuticals, Inc. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van MyMD Pharmaceuticals, Inc. van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE